Vera Therapeutics Stock Today
| VERA Stock | USD 27.70 0.36 1.32% |
PerformanceVery Weak
| Odds Of DistressLow
|
Vera Therapeutics is trading at 27.70 as of the 20th of March 2025, a 1.32 percent increase since the beginning of the trading day. The stock's open price was 27.34. Vera Therapeutics has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of May 2021 | Category Healthcare | Classification Health Care |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. The company has 63.75 M outstanding shares of which 8.36 M shares are at this time shorted by private and institutional investors with about 7.62 trading days to cover. More on Vera Therapeutics
Moving together with Vera Stock
Moving against Vera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Vera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVera Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vera Therapeutics' financial leverage. It provides some insight into what part of Vera Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vera Therapeutics (VERA) is traded on NASDAQ Exchange in USA. It is located in 8000 Marina Boulevard, Brisbane, CA, United States, 94005 and employs 112 people. Vera Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.79 B. Vera Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.75 M outstanding shares of which 8.36 M shares are at this time shorted by private and institutional investors with about 7.62 trading days to cover.
Vera Therapeutics currently holds about 131.93 M in cash with (134.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Check Vera Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Vera Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vera Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vera Therapeutics. Please pay attention to any change in the institutional holdings of Vera Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Vera Ownership Details
Vera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Kynam Capital Management, Lp | 2024-12-31 | 1.5 M | |
| Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.4 M | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 1.4 M | |
| First Light Asset Management, Llc | 2024-12-31 | 1.3 M | |
| Woodline Partners Lp | 2024-12-31 | 1.2 M | |
| Lord, Abbett & Co Llc | 2024-12-31 | 1.2 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.2 M | |
| Integral Health Asset Management, Llc | 2024-12-31 | 1.1 M | |
| Federated Hermes Inc | 2024-12-31 | 1.1 M | |
| Venbio Select Advisor Llc | 2024-12-31 | 5.6 M | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 4.4 M |
Vera Therapeutics Historical Income Statement
Vera Stock Against Markets
Vera Therapeutics Corporate Management
| Tad Thomas | Sr Manufacturing | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| Marshall MD | President, Founder | Profile | |
| Jason Carter | Chief Officer | Profile | |
| Julien JD | Senior Legal | Profile | |
| Joanne Curley | Chief Officer | Profile | |
| Kerry MD | Senior Affairs | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.